Transcript Russian Pharmaceutical Market Shulyak Sergey General Director DSM Group 15 April 2013 The result of 2012 year Source: DSM Group, audit of pharmaceutical market RF The result of.

Russian
Pharmaceutical Market
2012
Shulyak Sergey
General Director
DSM Group
15 April 2013
The result of 2012 year
Source: DSM Group, audit of pharmaceutical market RF
The result of 2012 year: units
Source: DSM Group, audit of pharmaceutical market RF
Per capita consumption of medicines in Russia
(pharma market)
Source: DSM Group, audit of pharmaceutical market RF
Retail segment is 74% Russian pharma market
Source: DSM Group, audit of pharmaceutical market RF
Retail segment in recent years, growing much faster
Source: DSM Group, audit of pharmaceutical market RF
Turnover of drags market is positive in EURO
Source: DSM Group, audit of pharmaceutical market RF
The largest contribution to the growth of pharma market structural change in favor of expensive drugs
Source: DSM Group, audit of pharmaceutical market RF
Retail drug market capacity in Russia and other
countries in 2012
Retail drug market = retail segment + reimbursement program
Source: DSM Group, audit of pharmaceutical market RF, open sources
Retail drug market capacity in Russia and other
countries in 2012
Retail drug market = retail segment + reimbursement program
Source: DSM Group, audit of pharmaceutical market RF, open sources
Per capita consumption of medicines in the world
(retail drug market)
Retail drug market = retail segment + reimbursement program
Source: DSM Group, audit of pharmaceutical market RF, open sources
Rating of drug manufacturing companies:
TOP 20 – 52,5%
2012
Ranking
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
Change
Manufacturer
Sales value,
million $.
Growth
Share
-4,7%
0,6%
-4,3%
4,6%
1,3%
10,6%
26,8%
-3,3%
6,5%
1,6%
12,4%
-3,4%
5,2%
2,2%
2,4%
8,0%
5,9%
6,6%
-8,7%
20,7%
5,5%
5,2%
3,6%
3,1%
3,0%
2,9%
2,8%
2,7%
2,7%
2,4%
2,3%
2,3%
2,2%
2,0%
2,0%
1,7%
1,7%
1,7%
1,5%
1,4%
2012
1
4
3
-
2
3
1
-
2
1
1
2
-
NOVARTIS
SANOFI
PHARMSTANDART
F.HOFFMANN-LA ROCHE
TEVA PHARMACEUTICAL
TAKEDA
ABBOTT
BAYER
BERLIN-CHEMIE
MERCK
PFIZER
GEDEON RICHTER
GLAXOSMITHKLINE
SERVIER
JANSSEN PHARMACEUTICA
STADA
BOEHRINGER INGELHEIM
KRKA
ASTRAZENECA
ASTELLAS PHARMA
Source: DSM Group, audit of pharmaceutical market RF
1 365,9
1 297,5
892,9
766,3
739,9
716,8
702,9
667,4
667,4
586,0
566,2
563,9
546,0
505,8
494,8
428,6
428,3
421,7
363,5
351,3
Rating of ATC classification
ATC level 2
Share, $
J01 ANTIBACTERIALS FOR SYSTEMIC USE
7,0%
L01 ANTINEOPLASTIC AGENTS
6,0%
L03 IMMUNOMODULATING AGENTS
4,1%
J05 ANTIVIRALS FOR SYSTEMIC USE
3,9%
M01 ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS
3,0%
ATC level 2
N02 ANALGESICS
Share, units
10,2%
J01 ANTIBACTERIALS FOR SYSTEMIC USE
9,3%
B05 PLASMA SUBSTITUTES AND PERFUSION SOLUTIONS
7,0%
D08 ANTISEPTICS AND DISINFECTANTS
5,1%
R01 NASAL PREPARATIONS
4,3%
Source: DSM Group, audit of pharmaceutical market RF
Quantity of drugs in the Russian pharma market
Quantity
The full name of the drug (SKU)
Retail segment
of medicines
Segment of
health care
institutions
Reimbursement
Pharma market
program
22 572
15 953
5 271
27 242
The trade name of the drug
6 916
5 616
2 349
7 700
The brand name of the drug
4 769
4 179
1 804
5 368
INN
1 914
1 803
802
2 053
The drug manufacturing company
1 087
873
450
1 191
Source: DSM Group, audit of pharmaceutical market RF
JSC “DSM Group”
Yamskogo Polya St. 7/2
Moscow, 125040
Russia
Contacts:
Sergey Shulyak [email protected]
Lilit Kotsinyan [email protected]
www.dsm.ru